Tafinlar + Mekinist

Active substance

Dabrafenib  + Trametinib

Holder

Novartis Pharma

Status

Closed

Indication

adjuvant treatment of high-risk BRAF V600 mutation-positive stage III melanoma after complete surgical resection

Public documents

Approbation

Information for the patient

Informed consent 

Last update

05/08/2019

Last updated on 13/02/2024